Attached files

file filename
EX-32.2 - EX-32.2 - Tarsus Pharmaceuticals, Inc.exhibit322.htm
EX-31.2 - EX-31.2 - Tarsus Pharmaceuticals, Inc.exhibit312.htm
EX-31.1 - EX-31.1 - Tarsus Pharmaceuticals, Inc.exhibit311.htm
10-Q - 10-Q - Tarsus Pharmaceuticals, Inc.tars-20200930.htm


Exhibit 32.1

CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Tarsus Pharmaceutials, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bobak Azamian, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act
of 1934, as amended; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and
result of operations of the Company.
Date: November 25, 2020
By:
/s/ Bobak Azamian, M.D., Ph.D.
Bobak Azamian, M.D., Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)